Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2
暂无分享,去创建一个
Brett K. Beaulieu-Jones | Florence T. Bourgeois | Robert W. Follett | Jeffery G. Klann | Harrison G. Zhang | R. Bellazzi | I. Kohane | G. Omenn | K. Ngiam | D. Hanauer | N. Gehlenborg | G. Weber | K. Wagholikar | S. L’Yi | S. Visweswaran | P. Avillach | L. Chiovato | A. Neuraz | F. Bourgeois | N. Palmer | A. Malovini | D. Zöller | Y. Ho | Kelly Cho | P. Schubert | C. Hong | G. Brat | D. Mowery | Hossein Estiri | V. Tibollo | A. Gutiérrez-Sacristán | B. Moal | L. Patel | Amelia L. M. Tan | Vincent Benoit | A. Dagliati | John H Holmes | W. Yuan | Harrison G Zhang | M. Morris | Shawn N Murphy | Xuan Wang | E. Schriver | A. South | M. Samayamuthu | Molei Liu | A. L. Tan | M. Hutch | R. Kavuluru | Bryce W. Q. Tan | T. Le | Clara-Lea Bonzel | B. W. Tan | Zongqi Xia | Yuan Luo | S. Maidlow | M. Pedrera-Jiménez | N. García-Barrio | S. Lozano-Zahonero | A. Makoudjou | F. J. Sanz Vidorreta | P. Serrano-Balazote | P. Tippmann | T. Cai | John H. Holmes | Shawn N. Murphy | B. Beaulieu-Jones | Pablo Serrano-Balazote | R. Follett | J. Holmes | S. Murphy | Trang T. Le | Noelia García-Barrio
[1] Jeffrey G. Klann,et al. Distinguishing Admissions Specifically for COVID-19 from Incidental SARS-CoV-2 Admissions: A National EHR Research Consortium Study , 2022, medRxiv.
[2] B. Luft,et al. Clinical risk factors for mortality in an analysis of 1375 patients admitted for COVID treatment , 2021, Scientific Reports.
[3] Jason W. Moore,et al. Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 , 2021, Scientific Reports.
[4] T. Zewotir,et al. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients , 2021, BMC Infectious Diseases.
[5] Seong-Ho Choi,et al. Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: A preliminary pilot study , 2021, PloS one.
[6] C. Fuentes-Orozco,et al. Risk factors for mortality of adult patients with COVID-19 hospitalised in an emerging country: a cohort study , 2021, BMJ Open.
[7] Jeffrey G. Klann,et al. International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: a 4CE Consortium Study (Preprint) , 2021 .
[8] M. Kivipelto,et al. Decreased Mortality Over Time During the First Wave in Patients With COVID-19 in Geriatric Care: Data From the Stockholm GeroCovid Study , 2021, Journal of the American Medical Directors Association.
[9] Xu-guang Guo,et al. Liver injury in COVID-19: clinical features and treatment management , 2021, Virology Journal.
[10] Jordan J. Clark,et al. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK , 2021, The Lancet Respiratory Medicine.
[11] L. Finelli,et al. Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020 , 2021, JAMA network open.
[12] S. Zeger,et al. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19 , 2021, JAMA network open.
[13] S. Pini,et al. Characteristics and outcomes in hospitalized COVID-19 patients during the first 28 days of the spring and autumn pandemic waves in Milan: An observational prospective study , 2021, Respiratory Medicine.
[14] J. Hochman,et al. C-reactive protein and clinical outcomes in patients with COVID-19 , 2021, European heart journal.
[15] Shaorui Shi,et al. Clinical and laboratory characteristics of severe and non‐severe patients with COVID‐19: A retrospective cohort study in China , 2021, Journal of clinical laboratory analysis.
[16] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .
[17] D. Asch,et al. Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic , 2020, JAMA internal medicine.
[18] C. Tebé,et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 , 2020, The New England journal of medicine.
[19] J. Rigdon,et al. Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during coronavirus disease 2019: beyond confounding. , 2020, Journal of hypertension.
[20] Samuel M. Brown,et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[21] H. Ohtsu,et al. First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics , 2020, Journal of Infection.
[22] S. Vollmer,et al. Improving Survival of Critical Care Patients With Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020* , 2020, Critical care medicine.
[23] R. Anderson,et al. Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.
[24] R. Malekzadeh,et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.
[25] Arthur S Slutsky,et al. Evaluation of PEEP and prone positioning in early COVID-19 ARDS , 2020, EClinicalMedicine.
[26] Arthur S Slutsky,et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. , 2020, JAMA.
[27] T. Ortel,et al. ISTH DIC subcommittee communication on anticoagulation in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.
[28] O. Tsang,et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[29] Jeffrey G. Klann,et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium , 2020, npj Digital Medicine.
[30] Leora I. Horwitz,et al. Trends in Covid-19 risk-adjusted mortality rates in a single health system , 2020, medRxiv.
[31] R. Schwartz,et al. Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area. , 2020, JAMA.
[32] A. Saqi,et al. Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data , 2020, Modern Pathology.
[33] M. Shankar-Hari,et al. Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland , 2020, American journal of respiratory and critical care medicine.
[34] S. Heydari,et al. Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis , 2020, European Journal of Medical Research.
[35] Jer Ping Ooi,et al. Risk factors for mortality among COVID-19 patients , 2020, Diabetes Research and Clinical Practice.
[36] Tingmei Wang,et al. Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests , 2020, Travel Medicine and Infectious Disease.
[37] Emily G McDonald,et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 , 2020, The New England journal of medicine.
[38] Bachti Alisjahbana,et al. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis , 2020, Therapeutic advances in respiratory disease.
[39] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[40] M. Thomeer,et al. Venous thromboembolism in SARS-CoV-2 patients: only a problem in ventilated ICU patients, or is there more to it? , 2020, European Respiratory Journal.
[41] F. S. Cardoso,et al. Liver injury in critically ill patients with COVID-19: a case series , 2020, Critical Care.
[42] Mickaël Ohana,et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.
[43] D. Goyal,et al. Early intervention likely improves mortality in COVID-19 infection. , 2020, Clinical medicine.
[44] Yi Wang,et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.
[45] S. Susen,et al. Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. , 2020, Circulation.
[46] Brett K. Beaulieu-Jones,et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium , 2020, npj Digital Medicine.
[47] Lei Liu,et al. COVID-19: Abnormal liver function tests , 2020, Journal of Hepatology.
[48] T. Jodlowski,et al. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.
[49] L. Tang,et al. Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis , 2020, Journal of Thrombosis and Thrombolysis.
[50] D. Raoult,et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial , 2020, International Journal of Antimicrobial Agents.
[51] Yi Yang,et al. Lower mortality of COVID-19 by early recognition and intervention: experience from Jiangsu Province , 2020, Annals of Intensive Care.
[52] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[53] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[54] R. Baric,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.
[55] Jamison D. Fargo,et al. Regional Variations in Documentation of Sexual Trauma Concepts in Electronic Medical Records in the United States Veterans Health Administration , 2019, AMIA.
[56] T. Kurth,et al. The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients , 2015, BMJ Open.
[57] G. Van den Berghe,et al. Cholestatic liver (dys)function during sepsis and other critical illnesses , 2015, Intensive Care Medicine.
[58] Philip Hall,et al. What is the Real Function of the Liver ‘Function’ Tests? , 2012, The Ulster medical journal.
[59] Stef van Buuren,et al. MICE: Multivariate Imputation by Chained Equations in R , 2011 .
[60] Trevor Hastie,et al. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. , 2011, Journal of statistical software.
[61] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[62] Tianxi Cai,et al. Evaluating Prediction Rules for t-Year Survivors With Censored Regression Models , 2007 .
[63] M. Kenward,et al. An Introduction to the Bootstrap , 2007 .
[64] H. Quan,et al. Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.
[65] R. Tibshirani. The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.
[66] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[67] J. Hoofnagle,et al. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. , 1988, Gastroenterology.
[68] M. Stone. Cross‐Validatory Choice and Assessment of Statistical Predictions , 1976 .